艾普奈珠单抗(Eptinezumab-JJMR) - 药物靶点：CGRP_在研适应症：偏头痛，丛集性头痛_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Eptinezumab、ALD-403、LU AG09221

+ [1]

靶点

CGRP

作用机制

CGRP拮抗剂(降钙素基因相关肽拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

H. Lundbeck A/SLundbeck Canada Inc.

Lundbeck Seattle BioPharmaceuticals, Inc.

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2020-02-21),

偏头痛

最高研发阶段(中国)临床3期

特殊审评-

登录后查看首次获批时间轴

序列信息

Sequence Code 156338L

来源: *****

Sequence Code 201708H

来源: *****

关联

41

项与艾普奈珠单抗相关的临床试验

NCT05937152 / Recruiting临床2期

CAT-Trial: CGRP Monoclonal Antibody for Treatment of Painful Diabetic Neuropathy: a Double-blind, Randomized, Placebo-controlled, International Multicenter, Phase II Clinical Trial

The main purpose of this study is to compare the change in pain intensity during treatment with a CGRP monoclonal antibody (eptinezumab) compared with placebo treatment in patients with painful diabetic polyneuropathy (DPN).

开始日期2024-04-01

申办/合作机构

Mayo Clinic

NCT05897320 / Recruiting临床3期

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine

The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.

开始日期2023-06-08

申办/合作机构

H. Lundbeck A/S

NCT05635604 / CompletedN/AIIT

Molecular Stratification of Signaling Pathways Underlying Migraine Pathophysiology.

To investigate whether administration of calcitonin gene-related peptide (CGRP) binding monoclonal antibodies eptinezumab prevents pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) induced migraine attacks in migraine without aura patients.

开始日期2023-03-01

申办/合作机构

Danish Headache Center

100 项与艾普奈珠单抗相关的临床结果

登录后查看更多信息

100 项与艾普奈珠单抗相关的转化医学

登录后查看更多信息

100 项与艾普奈珠单抗相关的专利（医药）

登录后查看更多信息

168

项与艾普奈珠单抗相关的文献（医药）

2024-02-29·Clinical Psychopharmacology and Neuroscience

Efficacy and Safety of Anti-CGRP Monoclonal Antibodies in Prevention of Chronic Migraine: A Bayesian Network Meta-analysis

Review

作者: Haridas, Mundot Puliappadamb ; Srinivasan, Anand ; Tripathy, Amruta ; Maiti, Rituparna

Due to the unmet needs in the management of migraine, a primary headache, and disabling disorder, the past decade has focused on developing monoclonal antibodies (mAbs) against the calcitonin-gene-related peptide (CGRP) as migraine prophylactic agents. The objective of the study was to evaluate the efficacy and safety of various anti-CGRP mAbs in the prevention of chronic migraine. Network meta-analysis (NMA) was performed using the Bayesian framework to estimate the efficacy and safety of mAbs after performing a literature search in PubMed, MEDLINE, Cochrane database, and International Clinical Trial Registry Platform (ICTRP). The outcomes calculated were in terms of mean difference (MD) or odds ratio (OR) with a 95% credible interval (95%CrI). Network graphs were constructed and node-split analysis was done to analyze the inconsistency. The NMA included a total of 10 clinical trials. Galacanezumab (120 mg) (MD: -2.7; 95%CrI: -4.8 to -0.83) was found to be better than other mAbs in terms of the difference in mean migraine days (MMD). Fremanezumab quarterly dose administration showed the best response (OR: 2.9; 95%CrI: 1.9 to 4.6) in terms of responder rate. Eptinezumab was found to be safer (OR: 0.88; 95%CrI: 0.61-1.3) as compared to other mAbs in terms of the rate of adverse events. Fremanezumab (quarterly) ranked better in terms of response rate, and eptinezumab was found to be the safest in the prophylactic management of migraine. Galacenequmab was better at reducing MMD. Further studies are needed to evaluate the long-term safety, efficacy, and use of mAbs in migraine patients.

2024-02-01·European Journal of Neurology

Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial

Article

作者: Mitsikostas, Dimos D ; Lipton, Richard B ; Ashina, Messoud ; Versijpt, Jan ; Ettrup, Anders ; Christoffersen, Cecilie Laurberg ; Sperling, Bjørn ; Sacco, Simona ; Ailani, Jessica

Abstract:

Background and purpose:

Eptinezumab reduced monthly migraine days more than placebo in the DELIVER study, a clinical trial with patients with difficult‐to‐treat migraine and prior preventive treatment failures. This post hoc analysis assesses the sustained response to eptinezumab at the population and patient level and evaluates the potential for response in initial non‐responders.

Methods:

Adults with chronic or episodic migraine and two to four prior preventive treatment failures were randomized to eptinezumab 100 mg, 300 mg or placebo every 12 weeks. Primary outcomes in this post hoc analysis are the proportion of patients with ≥30%, ≥50% or ≥75% reduction in monthly migraine days (i.e., migraine responder rates [MRRs]) during weeks 1–12 and weeks 13–24 and across 4‐week intervals. Secondary outcomes are maintenance and shifts in MRRs from weeks 1–12 to weeks 13–24.

Results:

Between weeks 1–12 and 13–24, ≥30% MRRs increased from 65.9% to 70.4% (100 mg) and from 71.0% to 74.5% (300 mg), versus 36.9% to 43.1% (placebo). The ≥50% and ≥75% MRRs were sustained or increased over the 24‐week period. The largest increase in ≥30% MRRs occurred after the second infusion with eptinezumab. The percentage of initial non‐responders (<30% MRRs during weeks 1–12) who experienced response (≥30% MRRs during weeks 13–24) to the second dose was 34.7% (100 mg) and 30.4% (300 mg) with eptinezumab versus 21.1% with placebo.

Conclusion:

Across MRR thresholds, most patients who responded to eptinezumab during weeks 1–12 maintained or improved response during weeks 13–24. More than one‐third of initial non‐responders became responders after their second infusion.

2024-01-01·Migraine Management

CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention

Review

作者: Alpuente, Alicia ; Pozo-Rosich, Patricia ; Caronna, Edoardo ; Torres-Ferrus, Marta

Migraine is a prevalent and disabling neurological disease. Its preventive treatment for decades has been rather limited due to the absence of disease-specific therapies with limited efficacy and tolerability. The advances made in migraine research have led to the discovery of the calcitonin gene-related peptide (CGRP) and its role in migraine pathophysiology. CGRP is a neuropeptide that acts as potent vasodilator and is involved in pain processing. Increased levels of plasma CGRP have been observed during migraine attacks as well as interictally when comparing patients with migraine and healthy controls. In the last years, two classes of drugs antagonizing CGRP have therefore been developed as the first migraine-specific preventive treatments: anti-CGRP monoclonal antibodies (mAbs) and gepants. Four mAbs have been approved: erenumab, galcanezumab, fremanezumab, and eptinezumab. Gepants are small molecules that antagonize the CGRP receptor; currently only rimegepant and atogepant have been approved for migraine prevention. These new drugs have demonstrated efficacy and safety in clinical trials for both episodic and chronic migraine, and results from their real-world experience are being increasingly reported in literature. In this review, we provide an overview of anti-CGRP drugs and their placement in migraine prevention.

48

项与艾普奈珠单抗相关的新闻（医药）

2024-03-20

·药时代

做了两年多的药企CEO，倦了

2023年2月9日，鲍勃·阿塞尔比（Bob Azelby）黯然离开了工作时长2年半的Eliem Therapeutics。鲍勃作为Eliem的首任CEO，与其同批离开的还有全司55%的员工。Eliem是一家十分年轻的公司，2019年在RA Capital Management、Access Biotechnology 等投资机构的资助下成立并一直处于隐匿模式。直至2023年3月，Eliem凭借一则“我司获得8000万美元融资”的新闻稿，正式对外亮相，那时鲍勃已然是该公司的CEO了。Eliem的定位十分清晰，专注于CNS治疗领域。尽管公司刚刚出道，但旗下已然拥有慢性疼痛治疗药物ETX-810（两项2a期临床进行中）、抗精神类药物ETX-155（即将启动多项2a期临床）两款候选药物。这对刚从Alder BioPharmaceuticals离开的鲍勃而言，可谓是“神仙开局”。不同于众多深耕CNS领域中的学术大佬，鲍勃是商务出生且工作履历颇为曲折。青年时期的鲍勃，先是在安进做了15年商务，后去了Juno Therapeutics做了3年首席商务官，但由于公司被Celgene Corporation收购，再次转战Alder BioPharmaceuticals，而鲍勃也是在这份工作履历中正式涉足CNS治疗领域。鲍勃是2018年加入Alder的，任CEO一职。彼时的Alder作为CNS领域明星企业，被灵北看中后，于2019年以近20亿美元收购，2020年FDA批准首款用于预防成人偏头痛药物eptinezumab（Alder原研）。尽管这段工作经历颇为短暂，但也成就了鲍勃在CNS治疗领域中的管理地位。Eliem的CEO，鲍勃“当仁不让”。时间来到2021年5月，即Eliem“出世”2个月后，公司再获6000万美元B轮融资，同年8月成功IPO，获9200万美元股权融资。鲍勃在2021年半年报中慷慨表示，“对于Eliem，这是激动人心的一年，我们将用这些资金去推动手中这些具有潜力的产品，致力于CNS治疗药物的开发。”然而，就是这般慷慨激昂的言论，2年后的鲍勃怎么也说不出了。在鲍勃任职Eliem CEO的2年时间里，核心管线相继受挫。先是进展最快的ETX-810在用于糖尿病周围神经性疼痛和腰骶神经根疼痛的两项2a试验失败（2022年8月停止开发），后是ETX-155在早期研究中出现CMC问题，多项临床研究被推迟。终于在2023年2月，Eliem宣布暂停ETX-155的开发（已经完成1期临床用于抑郁症研究），为了符合股东最佳利益，反而将研发重心再次转向聚焦临床前产品ETX-123，并裁员55%，这其中也包括鲍勃的离开。所谓“人挪活树挪死”。离开之后的鲍勃，加入了ADC Therapeutics、Cardinal Health等多家药企的董事会，日子要相比在Eliem作全职CEO时，相对安心。而Eliem在2023年7月宣布“计划探索战略代替方案”，并停掉了最后一个项目ETX-123。截止2023年6月30日，该公司拥有未经审计的初步现金、现金等价物及可流通证券投资总额约为 1.026 亿美元。可以说，Eliem正处在破产清算的边缘。直至2024年3月19日，Eliem宣布计划并购一家名为Tango的Biotech，初步估值为2000万美元，交易方式为股价换购。值得一提的是，Tango由RA Capital Management关联基金控制，而RA本身就是Eliem的大股东，此次收购有助于整合内部资源，降低未来发展的风险。当然，这一切，对于鲍勃没有太大关系了。点击这里，观看精彩直播！

临床2期IPO并购抗体药物偶联物临床3期

2024-03-12

·生物制品圈

一文读懂 | GPCR抗体开发的前景和挑战

导读：G 蛋白偶联受体（GPCR, G protein-coupled receptor）是细胞表面的膜蛋白家族，在人体及多种动物体内广泛存在。GPCR 参与多种疾病的发生机制，如癌症、神经疾病、代谢疾病、免疫疾病和炎症等。因此，GPCR是药物开发的重要靶点。然而，由于跨膜蛋白自身的特性，GPCR靶向药物（尤其是抗体）开发的最大挑战在于抗原的可及性，在体外很难获得具有生物活性的全长GPCR蛋白。今天的文章，菌菌总结了GPCR抗体开发的潜力和难点，包括GPCR抗体的应用前景、早期开发流程与面临的技术挑战。我们还汇总了当前的GPCR免疫原类型及优劣势，包括表达目标抗原的全细胞或细胞膜、VLP嵌合抗原、纯化后的抗原、DNA、以及最新技术驱动下的mRNA免疫原。 GPCR是最大的蛋白质超家族之一，由800多个家族成员组成。这类受体的结构特点是具有七个跨膜结构域。GPCR激动剂能够诱导其构象变化，激活其与下游信号蛋白（以异三聚体G蛋白为主）的结合。GPCR家族蛋白作用于多种细胞通路。据早期文献报道，约40%的上市药物通过GPCR介导其效应。 GPCR的化学特性、结构、信号和药理学有助于靶向药物的开发。2012年的诺贝尔化学奖授予了Brian Kobilka和Robert Lefkowitz，以表彰他们关于“G蛋白偶联受体功能方面的重要发现”。根据既往报道，超过200个GPCR靶点在临床前或临床研究中显示出特异性抗体开发的可行性，涵盖多疾病领域，如肿瘤、代谢疾病、炎症、呼吸道疾病、感染性疾病等。目前，FDA已批准3种靶向GPCR或GPCR相关配体的单克隆抗体用于非肿瘤适应症，分别为莫格利珠单抗（mogamulizumab, C-C 趋化因子受体4(CCR4)）、erenumab（抗降钙素基因相关肽(CGRP)1型受体）和eptinezumab（CGRP）。其他在研的GPCR抗体靶点包括但不限于C-C趋化因子受体7 (CCR7)、CCR5、C-X-C基序趋化因子受体2（CXCR2）、CXCR4、C-X3-C 趋化因子受体1（CX3CR1）、补体5a受体（C5aR）、G蛋白偶联受体（GPR20）、GPR56、β1-肾上腺素受体、胃泌素/胆囊收缩素B型受体（CCKBR）、趋化因子样受体1 （CMKLR1）、甲酰基肽受体1（FPR1）、胰高血糖素受体（GCGR）、蛋白酶激活受体4（PAR4）、富含亮氨酸重复单位的G蛋白偶联受体（LGR5）。抗体类药物的早期开发流程一般为抗原选择、抗原制备、动物免疫、抗体筛选和测序，以获得特异性抗体序列，随后进行抗体改造、体外试验、动物试验和临床试验验证。 2.1 GPCR抗原的选择和制备抗原发挥免疫原的作用，刺激宿主动物产生特异性抗体，随后通过一定的筛选手段进行鉴别。抗原的选择和制备是抗体开发的重要环节。目前，GPCR常用的免疫原种类包括：纯化的抗原、全细胞、细胞膜组分、病毒样颗粒（VLP）、合成多肽、DNA和mRNA。GPCR抗原的制备是一大技术难题，不同种类抗原的制备方式、免疫原性和特异性存在很大差异。 2.2 动物免疫与GPCR抗体筛选目标抗原制备完成后，下一步是进行动物免疫。常规单克隆抗体通常选择鼠、兔、羊等作为宿主动物进行抗原免疫；而纳米抗体（也称单域抗体）、重链抗体的筛选以羊驼或鲨鱼为代表。动物免疫的其他关键点包括宿主动物的年龄、抗原用量、注射方式和部位等。随着传统单克隆抗体、双特异性抗体、抗体偶联药物、纳米抗体的发展，抗体筛选技术也趋于成熟，包括杂交瘤技术、B细胞筛选技术、噬菌体展示技术、酵母展示技术等。我们可以通过以上方法得到抗体序列，包括可变区域的互补决定区（CDR）。 GPCR抗体的开发同样面临技术上的挑战，主要在于GPCR特异性抗原或抗原表位的可及性，及其与GPCR生物学的相关性。当前虽存在多种类型的抗原用于抗体的筛选，然而或多或少存在缺陷与不足。全细胞抗原、膜组分和VLP存在其他背景抗原的干扰，免疫原性和特异性差；纯化抗原较难制备；多肽类抗原完整性差；DNA抗原细胞核内递送困难、抗原表达水平低且依赖佐剂。依托mRNA这一近年趋向成熟的技术平台（核苷酸修饰和递送技术等不断优化），能够在目标宿主内表达天然有活性的GPCR蛋白。mRNA作为免疫原的独特优势，有望在GPCR抗体筛选中发挥有效作用，加速GPCR抗体成药的研发进程。参考文献 [1] Hutchings CJ, Koglin M, Olson WC, Marshall FH. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep;16(9):787-810. doi: 10.1038/nrd.2017.91. [2] Gulezian E, Crivello C, Bednenko J, Zafra C, Zhang Y, Colussi P, Hussain S. Membrane protein production and formulation for drug discovery. Trends Pharmacol Sci. 2021 Aug;42(8):657-674. doi: 10.1016/j.tips.2021.05.006. [3] Hutchings CJ. A review of antibody-based therapeutics targeting G protein-coupled receptors: an update. Expert Opin Biol Ther. 2020 Aug;20(8):925-935. doi: 10.1080/14712598.2020.1745770.[4] High P, Carmon KS. G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions. Cancer Lett. 2023 Jun 28;564:216191. doi: 10.1016/j.canlet.2023.216191. 内容来源于网络，如有侵权，请联系删除。

信使RNA细胞疗法

2024-03-11

·PRNewswire

American Headache Society Publishes Updated Guidance on Migraine Preventive Therapy

Recommends therapies targeting calcitonin gene-related peptide (CGRP) as a first-line option for migraine prevention MOUNT ROYAL, N.J., March 11, 2024 /PRNewswire/ -- The American Headache Society (AHS) published a consensus position statement today in Headache: The Journal of Head and Face Pain about the first-line role CGRP-targeting therapies should play in the prevention of migraine. Specifically, the AHS calls for CGRP-targeting therapies to be considered as a first-line approach for migraine prevention, along with previous first-line treatments, without a requirement for prior failure of other classes of migraine preventive treatment. The goal of preventive treatment is to reduce the frequency, intensity, duration, and disability associated with migraine attacks. AHS, the leading medical and scientific organization for healthcare professionals in migraine and other headache disorders, estimates that preventive therapy is indicated for approximately 40% of people with migraine, and many are unable to use existing first-line preventive migraine medicines due to limited effectiveness and tolerability. After a comprehensive review of clinical trial and real-world experience, the AHS found the evidence supporting the efficacy, tolerability, and safety of CGRP-targeting therapies—such as monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) and small-molecule CGRP receptor antagonists (rimegepant and atogepant)—for migraine prevention to be substantial in its volume, scope, and quality. "Moving CGRP-targeting therapies to the first line of treatment could have a transformational impact on the prevention of migraine attacks and their associated burdens," said Andrew Charles, MD, FAHS, position statement co-author and president of the American Headache Society. "Elevating CGRP-targeting therapies to the first line should reduce barriers for patients to receive these effective treatments and bring hope to countless people who experience this invisible, yet debilitating disease." The new position statement from the AHS, "Calcitonin gene-related peptide (CGRP)-targeting therapies are a first-line option for the prevention of migraine," provides guidance on how to integrate these treatments into clinical practice. ABOUT MIGRAINE Migraine is the third most common disease in the world. In the United States, an estimated 40 million Americans live with migraine. While migraine symptoms vary from person to person, common symptoms include severe headache; nausea and/or vomiting; increased sensitivity to light, sound, or smells; depressed mood or changes in mood; and yawning, fatigue, and difficulty sleeping. ABOUT THE AMERICAN HEADACHE SOCIETY The American Headache Society strives to improve the lives of people impacted by migraine and other headache disorders. The AHS is a professional society of health care providers dedicated to the study and treatment of headache and face pain. The Society's objective is to promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Educating physicians, health professionals, and the public while encouraging scientific research are the primary functions of our Society. Learn more at AmericanHeadacheSociety.org. This consensus statement published by the American Headache Society (AHS) is an assessment of current scientific and clinical information that is provided as an educational service. The information should not be considered inclusive of all appropriate treatments. New evidence may develop between the time this statement is submitted and when it is published or read. This statement addresses only the question that is specifically identified. It does not mandate any particular course of medical care and is not intended to substitute for the independent professional judgment of the treating provider. CONTACT Tanya Kiniry [email protected] SOURCE American Headache Society

100 项与艾普奈珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	艾普奈珠单抗	L01XC	DB14040

研发状态

适应症	最高研发状态	国家/地区	公司
偏头痛	批准上市	澳大利亚更多	Lundbeck Australia Pty Ltd. 更多
丛集性头痛	临床3期	挪威更多	H. Lundbeck A/S 更多
急性偏头痛	无进展	美国更多	H. Lundbeck A/S 更多
药物引起的头痛	无进展	中国更多	H. Lundbeck A/S 更多
继发性头痛症	无进展	格鲁吉亚更多	H. Lundbeck A/S 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04418765 (DELIVER, AAN2023)	临床3期	偏头痛	890	Eptinezumab 100mg	襯壓餘築製網鏇膚鹹鏇(範構鬱齋膚憲鬱願齋艱) = 繭醖衊範觸醖願範糧窪襯繭網獵鬱齋憲鏇襯衊 (醖獵糧選觸艱壓鬱積憲 )	-	2023-04-25
				Eptinezumab 300mg	襯壓餘築製網鏇膚鹹鏇(範構鬱齋膚憲鬱願齋艱) = 願鏇壓網蓋鹽範壓鏇夢襯繭網獵鬱齋憲鏇襯衊 (醖獵糧選觸艱壓鬱積憲 )
AAN2023	N/A	-	31	Eptinezumab 100mg	構鹽範襯鹹遞鹽廠繭膚(餘餘醖壓積醖蓋願衊築) = 77.4% reported that treatment improved disability/function after 6 months of use 願簾簾蓋願遞鏇願醖範 (糧鹽齋製觸壓糧製簾壓 ) 更多	积极	2023-04-25
NCT02974153 (PROMISE-2, AAN2023)	临床3期	偏头痛 \| 继发性头痛症	1,072	Eptinezumab 100mg	遞網鑰膚艱窪鬱壓醖觸(製壓夢積築襯顧壓鹹憲) = 構夢襯襯範齋襯鬱簾憲襯淵醖衊構顧範繭襯簾 (構膚鏇範夢齋廠餘繭糧 ) 更多	积极	2023-04-25
				Eptinezumab 300mg	遞網鑰膚艱窪鬱壓醖觸(製壓夢積築襯顧壓鹹憲) = 憲齋獵繭襯糧齋餘築製襯淵醖衊構顧範繭襯簾 (構膚鏇範夢齋廠餘繭糧 ) 更多
NCT02974153 \| NCT02559895 (PROMISE studies, Pubmed)	N/A	偏头痛	-	Eptinezumab 100 mg	觸餘鹽遞衊顧選膚鏇選(網憲襯獵簾製鬱壓觸夢) = 淵憲鬱獵廠鹹觸構夢醖鑰範顧範夢築簾襯網壓 (糧鑰簾願齋簾淵網鑰觸 )	-	2022-10-25
				Eptinezumab 300 mg	觸餘鹽遞衊顧選膚鏇選(網憲襯獵簾製鬱壓觸夢) = 顧築糧糧醖餘襯簾窪遞鑰範顧範夢築簾襯網壓 (糧鑰簾願齋簾淵網鑰觸 )
ANA2022	N/A	偏头痛	-	Eptinezumab 100mg	願積鏇艱願廠選鏇壓構(構齋鏇齋網廠簾繭願鑰) = 窪構簾製選淵願積鬱顧構餘築糧艱願蓋築糧壓 (餘簾鹹鬱選繭觸築衊襯 )	-	2022-09-14
				Eptinezumab 300mg	願積鏇艱願廠選鏇壓構(構齋鏇齋網廠簾繭願鑰) = 窪網網獵壓簾夢鹹構繭構餘築糧艱願蓋築糧壓 (餘簾鹹鬱選繭觸築衊襯 )
NCT02974153 (PROMISE-2, Pubmed)	临床3期	偏头痛	1,072	Eptinezumab 100mg	築製鹹繭構衊觸衊構壓(遞積蓋廠艱鑰襯範壓獵) = 鑰鹹憲願膚壓鏇襯餘艱範構膚醖蓋獵簾積憲餘 (齋獵壓鬱醖蓋獵蓋醖鹹 )	积极	2022-09-06
				Eptinezumab 300mg	餘淵艱壓齋顧窪淵簾選(糧構憲鹹衊築齋簾積鹹) = 獵鑰糧鹽鏇鏇網夢獵窪鑰觸構繭顧鏇簾鹽簾壓 (顧醖簾網獵選顧艱顧廠 ) 更多
NCT04152083 (RELIEF, Pubmed)	临床3期	偏头痛	485	Eptinezumab 100 mg	鏇鹹鏇網範壓壓獵製膚(艱網憲積餘構願糧餘顧) = 網窪淵積齋選鏇鑰獵鹹壓積窪餘糧鬱鏇遞觸獵 (鹽築選築憲築構夢醖範 )	积极	2022-07-28
				Placebo	鏇鹹鏇網範壓壓獵製膚(艱網憲積餘構願糧餘顧) = 遞窪艱衊壓範蓋襯壓鏇壓積窪餘糧鬱鏇遞觸獵 (鹽築選築憲築構夢醖範 )
NCT02985398 (PREVAIL, Pubmed)	临床3期	偏头痛	128	Eptinezumab	繭築構蓋廠糧鹹齋壓觸(獵鏇膚淵鏇選窪積蓋憲) = 顧窪衊夢簾鬱顧遞簾膚餘蓋衊製選醖醖膚糧獵 (壓蓋獵選簾觸衊選遞夢 ) 更多	-	2022-07-08
NCT04152083 (RELIEF, Pubmed) 人工标引	临床3期	偏头痛	480	eptinezumab	糧衊艱構鏇鬱積鹹獵壓(簾簾築製壓構鬱憲鬱艱) = 獵選繭憲製築鑰構醖遞網製鬱衊鹹網鬱願蓋餘 (窪壓廠鬱選蓋蓋繭廠網 ) 更多	积极	2022-06-03
				Placebo	糧衊艱構鏇鬱積鹹獵壓(簾簾築製壓構鬱憲鬱艱) = 醖廠獵衊衊顧鑰構顧構網製鬱衊鹹網鬱願蓋餘 (窪壓廠鬱選蓋蓋繭廠網 ) 更多
NCT02974153 (PROMISE-2, Pubmed \| J Headache Pain)	临床3期	偏头痛	1,121	Eptinezumab 100mg	齋顧齋蓋糧廠範蓋憲選(鏇選繭鏇顧憲構膚壓鬱) = 夢齋襯餘構獵襯簾鬱糧壓鬱襯艱積餘鹹鏇廠獵 (醖選廠蓋積網願廠鏇鹽 ) 更多	积极	2022-02-21
				Eptinezumab 300mg	齋顧齋蓋糧廠範蓋憲選(鏇選繭鏇顧憲構膚壓鬱) = 鑰艱襯膚獵鹽艱鹽選積壓鬱襯艱積餘鹹鏇廠獵 (醖選廠蓋積網願廠鏇鹽 ) 更多